ESR1 and breast cancer: Here we demonstrated that an anti-estrogen (fulvestrant), which is a standard of care treatment for ER+ breast cancer, can beneficially shift the immunologic landscape of the irradiated TME by significantly changing the numbers and activity of multiple immune cell populations, resulting in enhanced responses to ICIs, even when growth of these tumors does not respond to anti-estrogen therapy alone.